Project Grant HT94252410575
Award Date
9/1/24
Completion Date
8/31/26
Dollars Obligated
$750K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Australia
Similar Awards
This Project Grant award, in the amount of $659,922.00, was provided by the Defense Health Agency (DHA) under the Military Medical Research and Development federal grant program (CFDA 12.420). The award will fund a gene therapy research project at Macquarie University in Australia to develop a pathway for delaying the onset of neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS) through nuclear TDP-43 supplementation. The project will run from September 15, 2025 to September 14,...
The Department of the Army Medical Command awarded Macquarie University $999,748.80 under the Military Medical Research and Development federal grant program (CFDA 12.420) for the period of September 1, 2022 through August 31, 2025. The grant funding will support Macquarie University's project "QUINOLINONES AS A NOVEL THERAPEUTIC STRATEGY IN ALS" which aims to investigate medical solutions for amyotrophic lateral sclerosis (ALS) through the development of quinolinone compounds. The...
This federal Project Grant award of $1,117,328.00 was issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The University of Queensland in Australia. The grant will fund a research project focused on developing proteomic biomarkers for prognosis and progression monitoring of amyotrophic lateral sclerosis (ALS) disease. The project will be conducted from April 1, 2025 through March 31, 2027. The University of Queensland has a proven...
The University of Denver was awarded a $877,397 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "SYNTHETIC PROTEIN MIMETICS-BASED SPECIFIC TARGETING AND DEGRADATION OF TDP-43 AGGREGATION ASSOCIATED WITH ALS". This 2-year grant, with an award date of March 1, 2024 and a completion date of February 28, 2026, will support the university's research efforts to develop new treatments for amyotrophic...
The Defense Health Agency awarded a $1,397,266 project grant to The University of Queensland under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from March 1, 2023 through February 28, 2026 to develop peptide inhibitors targeting sodium channels for the treatment of Amyotrophic Lateral Sclerosis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming...
This federal Project Grant award of $1,392,575.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports a project by Sola Biosciences, Inc. to develop a protein folding-based gene therapy targeting TDP-43 for the treatment of amyotrophic lateral sclerosis (ALS). The project aims to transform healthcare for military service members and the public through innovative biomedical research, with a focus on developing medical solutions...
This federal Project Grant award, valued at $1,103,084.00, was issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The funding supports the development of a personalized blood-based diagnostic assay for early detection of Amyotrophic Lateral Sclerosis (ALS) at Arizona State University. The university will collaborate with a sub-awardee, Georgetown University, to conduct the research. The project aims to transform healthcare for...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $796,875 project grant to the University of Florida (UF) Division of Sponsored Research. The grant, awarded on April 1, 2024, supports the development of heterobifunctional degraders of TDP-43 as a novel therapeutic strategy for amyotrophic lateral sclerosis (ALS). Under this grant, the University of North Carolina at Chapel Hill (UNC-CH) Office of Sponsored Research is serving as a sub-awardee....
The Department of the Army Medical Command awarded a $1,180,437 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCLA's research to evaluate circulating cell-free DNA as a biomarker for diagnosing and tracking the progression of amyotrophic lateral sclerosis (ALS). The award began on March 1, 2024 and is scheduled for completion by February 28, 2026. Through this Project Grant, UCLA...
The Defense Health Agency awarded Thomas Jefferson University a $779,200 project grant under the Military Medical Research and Development program (CFDA 12.420) to conduct senotherapy research for amyotrophic lateral sclerosis (ALS) from April 1, 2023 through March 31, 2025. The grant will support basic, applied, and advanced biomedical research investigating medical solutions for ALS, consistent with the program's goals of transforming military and public health care through innovative...